Genmab — Marts 2021
-
-
Aktier/middag: Mærsk går frem efter sats på medicin i småsurt marked:
https://www.proinvestor.com/investornyt/673637/aktier-middag-maersk-gar-frem-efter-sats-pa-medicin-i-smasurt-marked -
in BioNTech results: BNT311/GEN1046 – Data from a first-in-human Phase 1/2a trial of BNT311 (PD-L1x4-1BB) in 61 heavily pretreated patients with advanced solid tumors was presented at the SITC conference in November 2020. We expect a data update from this trial in the second half of 2021.
BNT312/GEN1042 – We expect first data disclosure from the Phase 1/2a trial of BNT312 in solid tumors in the second half of 2021. -
Horizon Therapeutics plc to Resupply Market With TEPEZZA
(teprotumumab-trbw) for the Treatment of Thyroid Eye Disease (TED) Beginning in April https://ir.horizontherapeutics.com/news-releases/news-release-details/horizon-therapeutics-plc-resupply-market-tepezzar-teprotumumab -
So , if Jan says that Kesimpta launch process is already in full swing in the US - and things are going really well, and says that right now, it looks like the launch of Kesimpta is well on its way to becoming one of the fastest launches of a drug in multiple sclerosis,; does that give us an idea of size?
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind